At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
dasatinibdrug
Likely dose
dasatinib 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
In Brief
A Phase 2 clinical trial evaluating dasatinib for Melanoma (Skin). Completed, enrolled 81 participants across 153 sites.
Detailed Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma or acral melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma (Skin)
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2009
Primary CompletionMay 2016
Study CompletionDec 2020
TodayJul 2026
First PostedJun 19, 2008
Enrollment StartJul 2, 2009
Primary CompletionMay 6, 2016
Study CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.0 years ago
Interventions
dasatinibdrug
Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.